Article Text

PDF
FRI0411 Coadministration of bosentan has no effect on the pharmacokinetics of nintedanib
  1. S Wind1,
  2. G Simons1,
  3. J Bertulis1,
  4. C Coeck2
  1. 1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
  2. 2SCS Boehringer Ingelheim Comm.V., Brussels, Belgium

Abstract

Background Nintedanib is a potent intracellular inhibitor of tyrosine kinases that has been approved for the treatment of idiopathic pulmonary fibrosis and is being investigated as a treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD). Bosentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension, which is a common comorbidity of SSc-ILD.

Objectives To ascertain the effect of bosentan on the pharmacokinetics of nintedanib.

Methods In an open-label, single-centre study, healthy male subjects aged ≥18 and ≤55 years with a body mass index (BMI) ≥18.5 and ≤29.9 kg/m2 received a single dose of nintedanib 150 mg alone (period 1) followed by bosentan 125 mg twice daily (bid) for 8 days (bosentan loading dose phase on days 1–6) with a single dose of nintedanib 150 mg on day 7 (period 2). The primary endpoints were the maximum plasma concentration (Cmax) of nintedanib and the area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-tz) of nintedanib. The secondary endpoint was the AUC from time 0 extrapolated to infinity (AUC0–∞) for nintedanib.

Results Thirteen subjects (12 White; mean [SD] age 35.0 [9.8] years and BMI 24.5 [2.5] kg/m2) were treated. All subjects completed the planned observation period. Based on Cmax, AUC0-tz and AUC0–∞, exposure to nintedanib was similar after a single dose of nintedanib given alone or in combination with multiple doses of bosentan 125 mg bid (Table). Adverse events were reported in 4 subjects (30.8%) on nintedanib alone (period 1), 4 subjects (30.8%) on bosentan 125 mg bid (days 1–6 of period 2) and 2 subjects (15.4%) after administration of bosentan with nintedanib (days 7 and 8 of period 2). All adverse events were mild in intensity.

Conclusions Coadministration of bosentan 125 mg bid had no effect on the pharmacokinetics of a single dose of nintedanib 150 mg.

Disclosure of Interest S. Wind Employee of: Boehringer Ingelheim Pharma GmbH & Co. KG, G. Simons Employee of: Boehringer Ingelheim Pharma GmbH & Co. KG, J. Bertulis Employee of: Boehringer Ingelheim Pharma GmbH & Co. KG, C. Coeck Employee of: Boehringer Ingelheim Pharma GmbH & Co. KG

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.